Zymeworks Inc. (ZYME): Total Liabilities
$78.03M
As of 2025-12-31
$316.60M
As of 2026-06-30
-20.6%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $78.03M | -37.2% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $124.32M | +7.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $116.07M | -25.5% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $155.77M | +11.2% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $140.04M | n/a | 2023-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Zymeworks Inc. (ZYME) | 2025-12-31 | $78.03M | -37.2% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $130.07M | -6.1% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $305.93M | +3.9% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $23.85M | -11.7% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $20.65M | -27.6% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.91M | -13.7% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $2.08B | +35.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $191.91M | -4.1% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
Compare ZYME, ZVRA, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗